Similar to the cumulative survival analysis, this SNP showed significant differences, but in opposite direction to our initial association analysis; for overall PCa risk, high risk (tumour stage T3/T4 or Gleason Score ≥8 or PSA > 20 ng/mL) vs low risk disease (tumour stage ≤T1, Gleason Score ≤6, PSA < 10) OR = 1.58, 95% CI 1.42–1.76, P = 1.23 × 10−17, high risk vs intermediate risk (Gleason Score=7, PSA = 10–20) OR = 1.42, 95% CI 1.33–1.51, P = 1.41 × 10−26 and risk lethal vs controls OR = 1.33, 95% CI 1.16–1.51, P = 2.29 × 10−05 (Supplementary Table 2). The gene discussed is PROS1; the disease is posterior cortical atrophy.